NICE recommends rimegepant for treating acute migraine in adultsBMJ 2023; 382 doi: https://doi.org/10.1136/bmj.p2104 (Published 14 September 2023) Cite this as: BMJ 2023;382:p2104
- Gareth Iacobucci
- The BMJ
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the oral treatment rimegepant as a cost effective option for acute treatment of migraine in adults.1
Draft guidance published on 14 September recommends rimegepant (also called Vydura and made by Pfizer) for adults who have tried at least two triptans—a group of medicines used for treating migraine or headache—but found that they did not work well enough.
NICE said that around 13 000 people could benefit from this treatment on the NHS. It has previously recommended …